Multi-agent chemotherapy in advanced soft tissue sarcoma (STS) – A systematic review and meta-analysis

Bramwell VH, Anderson D, Charette ML, et al. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev 2003. CD003293. Ratan, 2016, Chemotherapy for soft tissue sarcoma, Cancer, 122, 2952, 10.1002/cncr.30191 Demetri, 2012, First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study, Eur J Cancer, 48, 547, 10.1016/j.ejca.2011.12.008 Judson, 2014, Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial, Lancet Oncol, 15, 415, 10.1016/S1470-2045(14)70063-4 Martin-Broto, 2016, Randomized phase II study of trabectedin and doxorubicin compared with doxorubicin alone as first-line treatment in patients with advanced soft tissue sarcomas: a Spanish group for research on sarcoma study, J Clin Oncol, 34, 2294, 10.1200/JCO.2015.65.3329 Ryan CW, Merimsky O, Agulnik M, et al. PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol 2016. Tap, 2016, Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial, Lancet, 388, 488, 10.1016/S0140-6736(16)30587-6 Zer, 2016, Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: end point selection, surrogacy, and quality of reporting, J Clin Oncol, 34, 1469, 10.1200/JCO.2015.64.3437 Deeks, 2001, Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests, BMJ, 323, 157, 10.1136/bmj.323.7305.157 Burnand, 1990, Indexes and boundaries for “quantitative significance” in statistical decisions, J Clin Epidemiol, 43, 1273, 10.1016/0895-4356(90)90093-5 O'Bryan, 1977, Dose response evaluation of adriamycin in human neoplasia, Cancer, 39, 1940, 10.1002/1097-0142(197705)39:5<1940::AID-CNCR2820390505>3.0.CO;2-0 Benjamin, 1993, Single-agent ifosfamide studies in sarcomas of soft tissue and bone: the M.D. Anderson experience, Cancer Chemother Pharmacol, 31, S174 Verma, 2008, Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma, Cancer Treat Rev, 34, 339, 10.1016/j.ctrv.2008.01.005 Verma, 2008, Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review, Cancer, 112, 1197, 10.1002/cncr.23302 Sivendran, 2014, Adverse event reporting in cancer clinical trial publications, J Clin Oncol, 32, 83, 10.1200/JCO.2013.52.2219 Edmonson, 1993, Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas, J Clin Oncol, 11, 1269, 10.1200/JCO.1993.11.7.1269 Santoro, 1995, Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group, J Clin Oncol, 13, 1537, 10.1200/JCO.1995.13.7.1537 Harwood, 2015, Targeted chemotherapy in bone and soft-tissue sarcoma, Orthop Clin North Am, 46, 587, 10.1016/j.ocl.2015.06.011 Dickson, 2013, Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma, J Clin Oncol, 31, 2024, 10.1200/JCO.2012.46.5476 Wagner, 2010, Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors, J Clin Oncol, 28, 835, 10.1200/JCO.2009.25.2981 Fletcher CDM, World Health Organization, International Agency for Research on Cancer: WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.